Abstract Library

#3000 Patients with Somatostatin Receptor Type 2-Negative Neuroendocrine Tumors Have Sustained Inferior Survival Rates in a Propensity Score-Matched Analysis

Introduction: Sufficient expression of somatostatin receptor type 2 (SST2) in neuroendocrine tumors (NETs) is crucial for treatment with unlabelled somatostatin analogues (SSAs), or peptide receptor radionuclide therapy (PRRT) using radio-labelled SSAs. Impaired prognosis has been described for SST2-negative NET patients, however studies comparing matched SST2-positive and -negative subjects are missing.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Refardt J

Authors: Refardt J, Zandee W, Brabander T, Feelders R, Franssen G,

Keywords: somatostatin receptor type 2, outcome, propensity score analysis, survival,

#2905 DNA Methyltransferase Inhibitor Hydralazine Induces Upregulation of Somatostatin Type 2 Receptors in Human Neuroendocrine Tumor Cells

Introduction: Epidrugs like DNA methyltransferase inhibitors (DNMTi) can increase somatostatin receptor type 2 (SST2) expression in neuroendocrine tumor (NET) cells in vitro and in vivo. This effect could be used for NET patients with low SST2 expression who are currently ineligible for somatostatin analogue (SSA) treatment. However, the DNMTi known to stimulate SST2 have either a high toxicity profile or are not yet approved.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Refardt J

Authors: Refardt J, Klomp I, van Koetsveld P, Dogan-Oruç F, de Herder W,

Keywords: somatostatin type 2 receptor, BON-1, GOT-1, upregulation, DNA methyltransferase inhibitor, histone deacetylase inhibitor, epigenetic,

#1097 Epigenetic Manipulation of the Somatostatin Receptor Type 2 in Neuroendocrine Tumor Cells

Introduction: The somatostatin receptor type 2 (sst2) is a target for treatment in patients with neuroendocrine tumors (NET). However, variability in tumoral sst2 expression might lead to variability in response. Epidrugs could increase sst2 levels and improve response to somatostatin analogues (SSA).

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Veenstra M, Van Koetsveld P, Dogan F, Farrell W, Vitale G,

Keywords: NET, sst2, epidrug, signaling,

#1075 Filamin-A Is Required for Somatostatin Receptor 2 (SST2) Stabilization, Signaling and Angiogenesis Regulation in Gastroenteropancreatic Neuroendocrine Tumors

Introduction: Somatostatin receptor type 2 (SST2) is the main pharmacological target for GEP-NETs. A subset of patients is resistant to somatostatin analogs (SSa), although the molecular mechanisms responsible for resistance are poorly understood. Several studies identified cytoskeleton protein as determinant in receptor anchoring and signaling

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Vitali E, Cambiaghi V, Loiarro F, Zerbi A, Colombo P,

Keywords: FLNA, SST2, GEP-NET,

#976 Upregulation of Somatostatin Receptor Type 2 Expression in Neuroendocrine Tumors by Epigenetic Modulation

Introduction: The somatostatin receptor type 2 (sst2) is a target for treatment of neuroendocrine tumors (NETs). However, epigenetic mechanisms might account for the high variability in sst2 expression and treatment response between patients.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Veenstra M, Van Koetsveld P, Farrell W, Dogan F, Waaijers A,

Keywords: GEP-NET, sst2, epigenetics,